Abstract Number: 753 • 2013 ACR/ARHP Annual Meeting
Validation Of The New Histopathological Classification Of ANCA Glomerulonephritis and Its Association With Renal Outcomes In a Paediatric Population
Background/Purpose: Anti-Neutrophil Cytoplasmic Antibody (ANCA) associated glomerulonephritides (ANCA GN) include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and Churg-Strauss. A novel histopathologic classification for GPA…Abstract Number: 754 • 2013 ACR/ARHP Annual Meeting
Outcome Of Kidney Transplantation In Paediatric Patients With ANCA Associated Glomerulonephritis: A Single-Center Experience
Background/Purpose: Kidney transplant outcomes for paediatric patients with end stage kidney disease (ESKD) secondary to ANCA GN, particularly granulomatosis with polyangiitis (GPA) and microscopic polyangiitis…Abstract Number: 755 • 2013 ACR/ARHP Annual Meeting
Survival Of Patients With ANCA-Associated Vasculitides In Chronic Dialysis In France From 2002 To 2011: Data From The National Rein Registry
Background/Purpose: Despite dramatic outcome improvement in ANCA-associated vasculitides (AAV), renal involvement is still leading to end-stage renal disease (ESRD) in 20-30% of patients. This study…Abstract Number: 760 • 2013 ACR/ARHP Annual Meeting
Cluster Analysis To Explore Clinical Subclassification Of Eosinophilic Granulomatosis With Polyangiitis (Churg–Strauss)
Background/Purpose: Results from descriptive studies of eosinophilic granulomatosis with polyangiitis (EGPA) suggest distinct clinical subclasses that may be determined by anti-neutrophil cytoplasmic antibody (ANCA) status.…Abstract Number: 729 • 2013 ACR/ARHP Annual Meeting
Role Of Innate Immunity In The Pathogenesis Of ANCA-Associated Vasculitis
Background/Purpose: Natural killer cells (NK) represent one of the main effectors of the innate immune response through the defense against viral infections and the production…Abstract Number: 733 • 2013 ACR/ARHP Annual Meeting
Plasma Levels Of Fibrin/Fibrinogen Degradation Products Might Be a Useful Indicator Of Disease Activity, Classification and Nephritis Complications In Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Background/Purpose: It is important to determine the biomarkers for assessing disease activity of patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Plasma levels of fibrin/fibrinogen…Abstract Number: 734 • 2013 ACR/ARHP Annual Meeting
The Significance Of Anti-Myeloperoxidase and Anti-Proteinase 3 Antibodies In The Absence Of Anti-Neutrophil Cytoplasmic Antibody Immunofluorescence Positivity
Background/Purpose: Identification of serum anti-neutrophil cytoplasmic antibodies (ANCA) for the detection of ANCA-associated vasculitis (AAV) is often performed by screening with indirect immunofluorescence (IF), followed…Abstract Number: 736 • 2013 ACR/ARHP Annual Meeting
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Associated With Systemic Sclerosis In Japan: A Review Of The Literature
Background/Purpose: Cases of Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) during the course of systemic sclerosis (SSc) have recently been reported. Japanese cases of AAV associated…Abstract Number: 149 • 2013 ACR/ARHP Annual Meeting
Comparative Proteomic Analysis Of Neutrophils From Patients With Microscopic Polyangiitis and Granulomatosis With Polyangiitis
Background/Purpose: Both microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) belong to ANCA-associated vasculitis (AAV), in which neutrophils are thought to be involved in their…Abstract Number: 738 • 2013 ACR/ARHP Annual Meeting
Pulmonary Fibrosis In ANCA-Associated Vasculitis
Background/Purpose: The association of pulmonary fibrosis (PF) with anti neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV), especially microscopic polyangiitis (MPA), is rare but related to poor…Abstract Number: 2383 • 2012 ACR/ARHP Annual Meeting
Rituximab As Induction and Maintenance Therapies for ANCA-Associated Vasculitis: A Multicenter Retrospective Study On 80 Patients
Background/Purpose: Rituximab has been shown to induce remission of ANCA-associated vasculitis (AAV). Our study was undertaken to 1) describe the clinical response of AAV to…Abstract Number: 2700 • 2012 ACR/ARHP Annual Meeting
A Multi-Center Study of the Appropriateness of Anti-Neutrophilic Cytoplasmic Antibody Testing
A Multi-Center Study of the Appropriateness of Anti-Neutrophilic Cytoplasmic Antibody TestingBackground/Purpose: Anti Neutrophil Cytoplasmic Antibody (ANCA) test is an Indirect Immunoflorescence test used as an…Abstract Number: 1774 • 2012 ACR/ARHP Annual Meeting
Identification of Target Antigens of Anti-Endothelial Cell Antibodies in Patients with ANCA-Associated Systemic Vasculitis: A Proteomic Approach
Background/Purpose: Anti-endothelial cell antibodies (AECA) are frequently detected in anti-neutrophil cytoplasm antibodies (ANCA)-associated systemic vasculitis (AAV) and are considered to play pathological roles but their…Abstract Number: 1652 • 2012 ACR/ARHP Annual Meeting
Rituximab Versus Azathioprine for Maintenance in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
Background/Purpose: Once ANCA-associated vasculitis (AAV) remission has been achieved with CS and cyclophosphamide (CYC), maintenance therapy usually relies on azathioprine (AZA) or methotrexate. However, 18-…Abstract Number: 1654 • 2012 ACR/ARHP Annual Meeting
Primary Endpoint Failure in the Rituximab in ANCA-Associated Vasculitis Trial
Primary Endpoint Failure in the Rituximab in ANCA-associated Vasculitis TrialBackground/Purpose: The RAVE trial demonstrated that rituximab (RTX) is non-inferior to cyclophosphamide (CYC) for remission induction…